We aimed to investigate which measures of prior viral suppression predicted uncontrolled viremia in patients on cART who started >1 antiretrovirals (ARV) after 1/1/2003. Methods 1,807 EuroSIDA patients on cART that started any ARV after January 1, 2003 were included. Baseline was defined as the date of starting a new ARV after January 1, 2003. Poisson regression, adjusted for appropriate confounding variables, was used to identify measures of viral suppression before baseline which predicted risk of uncontrolled viremia (viral load [VL] >500 copies/ml at least 6 months after baseline) after starting a new ARV. Measures of viral suppression before baseline were number of rebounds (VL >500 copies/ml), size of rebounds, time since last rebound, highest ever rebound, and the total time suppressed and percentage of time suppressed while on cART prior to baseline.
Purpose of the study
We aimed to investigate which measures of prior viral suppression predicted uncontrolled viremia in patients on cART who started >1 antiretrovirals (ARV) after 1/1/2003. Methods 1,807 EuroSIDA patients on cART that started any ARV after January 1, 2003 were included. Baseline was defined as the date of starting a new ARV after January 1, 2003. Poisson regression, adjusted for appropriate confounding variables, was used to identify measures of viral suppression before baseline which predicted risk of uncontrolled viremia (viral load [VL] >500 copies/ml at least 6 months after baseline) after starting a new ARV. Measures of viral suppression before baseline were number of rebounds (VL >500 copies/ml), size of rebounds, time since last rebound, highest ever rebound, and the total time suppressed and percentage of time suppressed while on cART prior to baseline.
Summary of results
At baseline patients had been on cART a median of 6.2 years (IQR 4.7-7.3), and had been exposed to a median of seven ARVs (IQR 5-9). The most common reasons for starting a new ARV was patient/physician choice (32%) and toxicities (31%); 66% were suppressed at baseline. 530 patients experienced uncontrolled viremia (400 whilst on cART) after starting a new ARV. The incidence of uncontrolled viremia was 13.7/100 PYFU (95% CI:12.5-14.9). Figure 1 show the crude incidence of uncontrolled viremia after stratification by the number of rebounds and the proportion of time fully suppressed while on cART prior to baseline. In adjusted models, the rate of uncontrolled viremia was lower in those with fewer viral rebounds before baseline (IRR per additional prior rebound = 1.12 (95% CI: 1.04-1.20), and with increasing time fully suppressed on cART prior to baseline (IRR per additional 10% suppressed = 0.86 (0.83-0.90). Higher rebound values and less time since last rebound also increased the risk of uncontrolled viremia but were not significant after adjustment for time suppressed and number of previous rebounds. The results were consistent between patients suppressed and unsuppressed at baseline.
Conclusion
The number of previous rebounds and the percentage of time suppressed whilst on cART were both strong predictors of future uncontrolled viremia after starting a new ARV. Hence, the history of patterns of viral response to cART regimens should be an integrated component in
